# Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

> **NCT02751385** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 2 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Microgynon
- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT02751385
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-20
- **Primary completion:** 2017-11-28
- **Final completion:** 2017-11-28
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Terminated- Study halted due to low recruitment.
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02751385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02751385, "Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02751385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*